A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess The Efficacy, Safety, and Tolerability of VK2809 Administered for 12 Weeks Followed by a 4-Week Off-Drug Phase in Patients With Primary Hypercholesterolemia and Non-Alcoholic Fatty Liver Disease
Latest Information Update: 15 Oct 2020
At a glance
- Drugs VK 2809 (Primary)
- Indications Hypercholesterolaemia; Non-alcoholic fatty liver disease
- Focus Proof of concept; Therapeutic Use
- Sponsors Viking Therapeutics
- 29 Aug 2020 Results of liver fat assessments taken at 16 weeks; 4-weeks post-completion of dosing, presented at The International Liver Congress 2020
- 28 Aug 2020 According to a Viking Therapeutics media release, data from this study were presented at the Digital International Liver Congress .
- 28 Aug 2020 Results published in the Viking Therapeutics media release